Headache and Migraine

Fremanezumab-vfrm (Ajovy) receives FDA approval for the prevention of episodic migraine for patients aged 6 to 17 years.

Investigators find that erenumab, a calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, is not a preventive treatment for chronic cluster headache.

Topline results from a phase 3 trial showed 64.1% of patients on atogepant achieved a 50% or greater reduction in mean monthly migraine days during months 4 to 6.

Triptans are often a first-line treatment for migraine and can be used to treat menstrual migraine and cluster headaches.

Dihydroergotamine (Brekiya) is an acute treatment to help relieve migraine attacks, and it can come in nasal sprays, injections, and intravenous infusions.

Investigators found that zonisamide was associated with a reduction in monthly migraine days for pediatric populations.

Meloxicam and rizatriptan (Symbravo, formerly AXS-07) is a CGRP medication approved for the acute treatment of migraine with or without aura.

Axsome Therapeutics expects the therapy to be commercially available in the United States in approximately 4 months.

The calcitonin gene-related peptide monoclonal antibody significantly reduced the number of monthly migraine days.

No medications were associated with improved quality of life or reduced headache duration.

New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.

Patients with chronic migraine can frequently overuse acute medications, leading to medication overuse headaches.

Whereby gastroparesis can hinder the absorption of oral medications in the stomach, Tonix Pharmaceuticals is promoting alternative migraine treatments that bypass the digestive system.

Click Therapeutics announced that CT-132 met its primary endpoint in the phase 3 ReMMi-D trial.

Dive in and learn more about the answers to yesterday’s quiz.

Test your knowledge of migraine therapies.

Dive in and learn more about the answers to yesterday’s quiz.

For Migraine and Headache Awareness Month, Drug Topics spoke with Shivang Joshi, MD, MPH, RPh, FAHS to debunk migraine myths and explore resources to promote migraine awareness and education.

Test your knowledge of different migraine triggers.

A poster presented at AHS 2024 found that older patients tended to have more vitamin deficiencies compared to younger patients.

Dive in and learn more about the answers to yesterday’s quiz.

Test your knowledge different headache types.

Check out this list of resources to share with patients who are managing a migraine or other headache diagnosis.

These populations are also more likely to receive opioid analgesic therapies.